ASH 2016 Complete Coverage

A Glimpse of ASH

A Glimpse of ASH

Dr Isabel Cunningham discusses some of the important studies presented at the 2016 ASH meeting.

Idarubicin + HDAC ± Vorinostat Not Superior to 7+3 in AML

Idarubicin + HDAC ± Vorinostat Not Superior to 7+3 in AML

Idarubicin plus high-dose cytarabine (HDAC) with or without vorinostat was not superior to 7+3 chemotherapy.

Nilotinib Discontinuation Following Deep Molecular Response

Nilotinib Discontinuation Following Deep Molecular Response

Some patients with chronic myeloid leukemia (CML) who have maintained deep molecular responses for at least 2 years can safely discontinue nilotinib.

TKI Cessation Appears Feasible, Safe in Patients With CML

TKI Cessation Appears Feasible, Safe in Patients With CML

Tyrosine kinase inhibitor (TKI) cessation appears feasible and safe in patients with chronic myeloid leukemia in chronic phase (CML-CP).

No Impact of Detectable Disease on MRFS After Imatinib Cessation in CML

No Impact of Detectable Disease on MRFS After Imatinib Cessation in CML

There were no differences in molecular relapse-free survival between patients with prior 4.5 log reduction but detectable disease and those with undetectable disease

CML-CP: Second TKI Discontinuation Safe and Successful

CML-CP: Second TKI Discontinuation Safe and Successful

Tyrosine kinase inhibitors (TKIs) can be safely and successfully discontinued a second time despite failing first discontinuation.

ATRA + Arsenic Trioxide Active in Acute Promyelocytic Leukemia

ATRA + Arsenic Trioxide Active in Acute Promyelocytic Leukemia

All-trans retinoic acid (ATRA) plus arsenic trioxide with or without chemotherapy induces high remission rates.

Imatinib Generics Appear Non-inferior to Gleevec Brand Formulation in CML-CP

Imatinib Generics Appear Non-inferior to Gleevec Brand Formulation in CML-CP

Generic formulations of imatinib appear to be non-inferior to Novartis's Gleevec brand formulation with respect to clinical efficacy and tolerability.

Serum Free Light Chain Responses Better for Predicting Clinical Outcomes

Serum Free Light Chain Responses Better for Predicting Clinical Outcomes

Serum free light chain measurements correlate more closely with clinical outcomes than urine assessments in patients with light chain multiple myeloma.

Obinutuzumab-based Therapy Prolongs PFS in Untreated Follicular Lymphoma

Obinutuzumab-based Therapy Prolongs PFS in Untreated Follicular Lymphoma

Obinutuzumab-based induction and maintenance chemoimmunotherapy significantly improved progression-free survival.

Lower Intensity Intensification Therapy in Childhood ALL

Lower Intensity Intensification Therapy in Childhood ALL

Pediatric patients with acute lymphoblastic lymphoma (ALL) at standard risk for relapse do not benefit from lower-intensity, delayed intensification therapy.

Study Highlights Importance of Achieving CR After Intensive Therapy for AML

Study Highlights Importance of Achieving CR After Intensive Therapy for AML

Patients with acute myeloid leukemia (AML) who achieve complete remission have improved overall survival.

No Induction Therapy Superior to Another for Higher-risk AML, MDS

No Induction Therapy Superior to Another for Higher-risk AML, MDS

In higher-risk patients who fail hypomethylating agent treatment, no induction strategy is superior to another with respect to outcomes and safety.

Condensed HDAC Schedule Superior to Standard Schedule in AML

Condensed HDAC Schedule Superior to Standard Schedule in AML

Consolidation therapy with a condensed schedule of high-dose cytarabine (HDAC) is superior to a standard schedule.

Higher Idarubicin Dose During Consolidation Improves Leukemia-free Survival in AML

Higher Idarubicin Dose During Consolidation Improves Leukemia-free Survival in AML

A higher dose of idarubicin during consolidation therapy improves leukemia-free survival without increasing non-hematologic toxicity.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs